Literature DB >> 33164326

Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Nina Butkovich1, Enya Li1, Aaron Ramirez1, Amanda M Burkhardt2, Szu-Wen Wang1,3.   

Abstract

Infectious diseases are a major threat to global human health, yet prophylactic treatment options can be limited, as safe and efficacious vaccines exist only for a fraction of all diseases. Notably, devastating diseases such as acquired immunodeficiency syndrome (AIDS) and coronavirus disease of 2019 (COVID-19) currently do not have vaccine therapies. Conventional vaccine platforms, such as live attenuated vaccines and whole inactivated vaccines, can be difficult to manufacture, may cause severe side effects, and can potentially induce severe infection. Subunit vaccines carry far fewer safety concerns due to their inability to cause vaccine-based infections. The applicability of protein nanoparticles (NPs) as vaccine scaffolds is promising to prevent infectious diseases, and they have been explored for a number of viral, bacterial, fungal, and parasitic diseases. Many types of protein NPs exist, including self-assembling NPs, bacteriophage-derived NPs, plant virus-derived NPs, and human virus-based vectors, and these particular categories will be covered in this review. These vaccines can elicit strong humoral and cellular immune responses against specific pathogens, as well as provide protection against infection in a number of animal models. Furthermore, published clinical trials demonstrate the promise of applying these NP vaccine platforms, which include bacteriophage-derived NPs, in addition to multiple viral vectors that are currently used in the clinic. The continued investigations of protein NP vaccine platforms are critical to generate safer alternatives to current vaccines, advance vaccines for diseases that currently lack effective prophylactic therapies, and prepare for the rapid development of new vaccines against emerging infectious diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology-Inspired Nanomaterials > Protein and Virus-Based Structures.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  antigen delivery; immune response; infectious disease vaccines; protein nanoparticles; virus-like particles

Mesh:

Substances:

Year:  2020        PMID: 33164326      PMCID: PMC8052270          DOI: 10.1002/wnan.1681

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  180 in total

1.  Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c mice.

Authors:  Yicun Wang; Quanping Su; Shuai Dong; Hongxi Shi; Xiang Gao; Li Wang
Journal:  Hum Vaccin Immunother       Date:  2014-01-21       Impact factor: 3.452

2.  Developing Covid-19 Vaccines at Pandemic Speed.

Authors:  Nicole Lurie; Melanie Saville; Richard Hatchett; Jane Halton
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

Review 3.  The current picture of the structure and assembly of tobacco mosaic virus.

Authors:  P J Butler
Journal:  J Gen Virol       Date:  1984-02       Impact factor: 3.891

4.  Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.

Authors:  Punnee Pitisuttithum; Sorachai Nitayaphan; Suwat Chariyalertsak; Jaranit Kaewkungwal; Peter Dawson; Jittima Dhitavat; Benjaluck Phonrat; Siriwat Akapirat; Nicos Karasavvas; Lindsay Wieczorek; Victoria Polonis; Michael A Eller; Poonam Pegu; Dohoon Kim; Alexandra Schuetz; Surat Jongrakthaitae; Yingjun Zhou; Faruk Sinangil; Sanjay Phogat; Carlos A Diazgranados; James Tartaglia; Elizabeth Heger; Kirsten Smith; Nelson L Michael; Jean-Louis Excler; Merlin L Robb; Jerome H Kim; Robert J O'Connell; Sandhya Vasan
Journal:  Lancet HIV       Date:  2020-02-06       Impact factor: 12.767

5.  Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa.

Authors:  J Staczek; M Bendahmane; L B Gilleland; R N Beachy; H E Gilleland
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

6.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.

Authors:  Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

7.  Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.

Authors:  Z Durrani; T L McInerney; L McLain; T Jones; T Bellaby; F R Brennan; N J Dimmock
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

8.  Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.

Authors:  Kwaku Poku Asante; Daniel Ansong; Seyram Kaali; Samuel Adjei; Marc Lievens; Lydia Nana Badu; Prince Agyapong Darko; Patrick Boakye Yiadom Buabeng; Owusu Boahen; Theresa Maria Rettig; Clara Agutu; Samuel Benard Ekow Harrison; Yaw Ntiamoah; Japhet Adomako Anim; Elisha Adeniji; Albert Agordo Dornudo; Emilia Gvozdenovic; David Dosoo; David Sambian; Harry Owusu-Boateng; Elvis Ato Wilson; Frank Prempeh; Pascale Vandoolaeghe; Lode Schuerman; Seth Owusu-Agyei; Tsiri Agbenyega; Opokua Ofori-Anyinam
Journal:  Vaccine       Date:  2020-03-17       Impact factor: 3.641

9.  Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

Authors:  B Moss; G L Smith; J L Gerin; R H Purcell
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

10.  Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine.

Authors:  David A G Skibinski; Leigh Ann Jones; Yuan O Zhu; Lin Wu Xue; Bijin Au; Bernett Lee; Ahmad Nazri Mohamed Naim; Audrey Lee; Nivashini Kaliaperumal; Jenny G H Low; Lawrence S Lee; Michael Poidinger; Philippe Saudan; Martin Bachmann; Eng Eong Ooi; Brendon J Hanson; Veronica Novotny-Diermayr; Alex Matter; Anna-Marie Fairhurst; Martin L Hibberd; John E Connolly
Journal:  Sci Rep       Date:  2018-12-20       Impact factor: 4.379

View more
  6 in total

Review 1.  Emerging vaccine nanotechnology: From defense against infection to sniping cancer.

Authors:  Chan Feng; Yongjiang Li; Bijan Emiliano Ferdows; Dylan Neal Patel; Jiang Ouyang; Zhongmin Tang; Na Kong; Enguo Chen; Wei Tao
Journal:  Acta Pharm Sin B       Date:  2022-01-04       Impact factor: 14.903

Review 2.  Enhanced Immune Responses by Virus-Mimetic Polymeric Nanostructures Against Infectious Diseases.

Authors:  Xinpei Li; Shengqiu Liu; Panchao Yin; Kun Chen
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

Review 3.  Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy.

Authors:  Xuejiao Han; Aqu Alu; Hongmei Liu; Yi Shi; Xiawei Wei; Lulu Cai; Yuquan Wei
Journal:  Bioact Mater       Date:  2022-01-19

Review 4.  Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases.

Authors:  Hasnat Tariq; Sannia Batool; Saaim Asif; Mohammad Ali; Bilal Haider Abbasi
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

5.  Vaccine Efficacy of Self-Assembled Multimeric Protein Scaffold Particles Displaying the Glycoprotein Gn Head Domain of Rift Valley Fever Virus.

Authors:  Paul J Wichgers Schreur; Mirriam Tacken; Benjamin Gutjahr; Markus Keller; Lucien van Keulen; Jet Kant; Sandra van de Water; Yanyin Lin; Martin Eiden; Melanie Rissmann; Felicitas von Arnim; Rebecca König; Alexander Brix; Catherine Charreyre; Jean-Christophe Audonnet; Martin H Groschup; Jeroen Kortekaas
Journal:  Vaccines (Basel)       Date:  2021-03-23

Review 6.  Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19.

Authors:  Arjun Sharma; Konstantinos Kontodimas; Markus Bosmann
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.